A meta-analysis of apremilast on psoriatic arthritis long-term assessment of clinical efficacy (PALACE)

References

• Busse K, Liao W. Which psoriasis patients develop psoriatic arthritis? Psoriasis Forum. 2010;16:17–25.
   PubMedGoogle Scholar
• Palfreeman AC, McNamee KE, McCann FE. New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast. Drug Des Devel Ther. 2013;7:201–210.
   PubMed Web of Science ®Google Scholar
• Edson-Heredia E, Zhu B, Lefevre C, et al. Prevalence and incidence rates of cardiovascular, autoimmune, and other diseases in patients with psoriatic or psoriatic arthritis: a retrospective study using clinical practice research datalink. J Eur Acad Dermatol Venereol. 2015;29:955–963.
   PubMed Web of Science ®Google Scholar
• Costa L, Caso F, Ramonda R, et al. Metabolic syndrome and its relationship with the achievement of minimal disease activity state in psoriatic arthritis patients: an observational study. Immunol Res. 2015;61:147–153.
   PubMed Web of Science ®Google Scholar
• Caso F, Costa L, Del Puente A, et al. Psoriatic arthritis and TNF inhibitors: advances on effectiveness and toxicity. Expert Opin Biol Ther. 2015;15:1–2.
   PubMed Web of Science ®Google Scholar
• Soubrier A-S, Bele-Philippe P, Cortet B, et al. Treatment response, drug survival and safety of anti-tumour necrosis factor αtherapy in 193 patients with psoriatic arthritis: A twelve-year “real life” experience. Joint Bone Spine. 2015;82:31–37.
   PubMed Web of Science ®Google Scholar
• Caso F, Del Puente A, Peluso R, et al. Emerging drugs for psoriatic arthritis. Expert Opin Emerg Drugs. 2016;21:69–79. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Caso F, Lubrano E, Del Puente A, et al., et al. Progress in understanding and utilizing TNF-α inhibition for the treatment of psoriatic arthritis. Expert Rev Clin Immunol. 2016;12(3):315–331.
   PubMed Web of Science ®Google Scholar
• Costa L, Caso F, Atteno M, et al. Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients. Clin Rheumatol. 2014;33:833–839.
   PubMed Web of Science ®Google Scholar
• Smith JR, Levinson RD, Holland GN, et al. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum. 2001;45:252–257.
   PubMed Web of Science ®Google Scholar
• Olivieri I, Cantini F, Castiglione F, et al. Italian expert panel on the management of patients with coexisting spondyloarthritis and inflammatory bowel disease. Autoimmun Rev. 2014;13:822–830.
   PubMed Web of Science ®Google Scholar
• Schett G, Sloan VS, Stevens RM, et al. Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases. Ther Adv Musculoskelet Dis. 2010;2:271–278.
   PubMedGoogle Scholar
• Poole RM, Ballantyne AD. Apremilast: first global approval. Drugs. 2014;74:825–837.
   PubMed Web of Science ®Google Scholar
• Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1–12.
   PubMedGoogle Scholar
• Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. Bmj. 2003;327:557–560.
   PubMed Web of Science ®Google Scholar
• Papp KA, Kaufmann R, Thaci D, et al. Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study. J Eur Acad Dermatol Venereol. 2013;27:e376–83.
   PubMed Web of Science ®Google Scholar
• Papp K, Cather JC, Rosoph L, et al. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. Lancet. 2012;380:738–746.
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Strober B, Krueger JG, et al. An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast. Curr Med Res Opin. 2008;24:1529–1538.
   PubMed Web of Science ®Google Scholar
• Samrao A, Berry TM, Goreshi R, et al. A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults. Arch Dermatol. 2012;148:890–897.
   PubMed Web of Science ®Google Scholar
• Pathan E, Abraham S, Van Rossen E, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis. Ann Rheum Dis. 2013;72:1475–1480.
   PubMed Web of Science ®Google Scholar
• De Souza A, Strober BE, Merola JF, et al. Apremilast for discoid lupus erythematosus: results of a phase 2, open-label, single-arm, pilot study. J Drugs Dermatol. 2012;11:1224–1226.
   PubMed Web of Science ®Google Scholar
• Strand V, Fiorentino D, Hu C, et al. Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study. Health Qual Life Outcomes. 2013;11:82.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014;73:1020–1026.
   PubMed Web of Science ®Google Scholar
• Clinicaltrials.gov. Study NCT01212757. Efficacy and safety study of apremilast to treat active psoriatic arthritis (PALACE2); [ cited 2014 Nov 1]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01212757?rank=1&term=NCT01212757
   Google Scholar
• Clinicaltrials.gov. Study NCT01212770. PALACE3: Efficacy and safety study of apremilast to treat active psoriatic arthritis; [ cited 2014 Nov 1]. Available from: http://www.clinicaltrials.gov/show/NCT01212770.
   Google Scholar
• Clinicaltrials.gov. Study NCT01307423. Efficacy and safety study of apremilast to treat active psoriatic arthritis (PsA) (PALACE4). [ cited 2014 Nov 1]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01307423?rank=1&term=NCT01307423
   Google Scholar
• Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52:3279–3289.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004;50:2264–2272.
   PubMed Web of Science ®Google Scholar
• Antoni C, Krueger GG, De Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis. 2005;64:1150–1157.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. 2009;60:976–986.
   PubMed Web of Science ®Google Scholar